ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0949

Single-Cell RNA Sequencing of APS Skin Reveals Endothelial Pathology and Cellular Interactions
Abstract Number: 0545

SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells
Abstract Number: 1845

Six-minute Walk Test as a Prognostic Marker in Systemic Sclerosis
Abstract Number: 0382

Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Abstract Number: 0723

Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness
Abstract Number: 0315

Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
Abstract Number: 0985

Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers
Abstract Number: 1935

Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome
Abstract Number: 1506

SLAMF6 Compartmentalization Regulates Autoimmune T Cell Responses
Abstract Number: 0885

SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment
Abstract Number: 1739

SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials
Abstract Number: 0308

Sleep Disorders and Serum Brain-derived Neurotrophic Factor Levels in Patients with Primary Sjögren’s Syndrome
Abstract Number: 1590

Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and Chronic Inflammatory Diseases
Abstract Number: 0830

Smartphone Assisted Patient Initiated Care Safely Reduces Outpatient Clinic Visits in Patients with Rheumatoid Arthritis: Results from a Randomized Controlled Trial
Abstract Number: 0615

Socioeconomic Characteristics Associated with Electronic Health Care Utilization in an Urban Rheumatology Clinic During the COVID-19 Pandemic

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].